• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Autolus Therapeutics Plc ADR (NQ: AUTL )

    3.815 +0.015 (+0.39%)
    Streaming Delayed Price Updated: 11:14 AM EDT, Apr 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,943,231
    Open 3.740
    Bid (Size) 3.810 (25)
    Ask (Size) 3.820 (22)
    Prev. Close 3.800
    Today's Range 3.610 - 3.830
    52wk Range 1.780 - 7.450
    Shares Outstanding 52,346,231
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
    From Autolus Therapeutics plc
    Via GlobeNewswire

    Performance

    YTD
    -44.23%
    -44.23%
    1 Month
    -32.83%
    -32.83%
    3 Month
    -37.87%
    -37.87%
    6 Month
    +40.26%
    +40.26%
    1 Year
    +105.11%
    +105.11%

    More News

    Read More
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Breaking Down Autolus Therapeutics: 4 Analysts Share Their Views
    Via Benzinga
    Autolus Therapeutics's Earnings Outlook
    Via Benzinga
    Analyst Expectations for Autolus Therapeutics's Future
    Via Benzinga
    Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Autolus Therapeutics Announces Changes to its Board of Directors
    From Autolus Therapeutics plc
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Autolus Therapeutics announces publication in Blood Cancer Journal
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Earnings Scheduled For March 14, 2024
    Via Benzinga
    Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Autolus Therapeutics announces publication in Nature Communications
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Autolus Announces Pricing of Underwritten Offering
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Autolus Therapeutics announces publication in ACS Chemical Biology
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Chart Of The Day: Autolus Therapeutics - Effective Cancer Treatments
    Via Talk Markets
    Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors
    From Autolus Therapeutics plc
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Autolus Therapeutics Announces Changes to its Board of Directors
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
    From Autolus Therapeutics plc
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.